REGIS UNIVERSITY NU 641 ADVANCED CLINICAL PHARMACOLOGY EXAM 2 QUESTIO… EXAM
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
Regis University NU 641
Advanced Clinical
Pharmacology Exam 2
Questions & Answers 2026-
2027 (Rationales)
Verified Answers Exam Ready With Rationales
55 QUESTIONS
DOCUMENT OVERVIEW
This document presents 55 advanced clinical pharmacology exam questions, complete with correct
answers and detailed rationales. It is a valuable study resource for nursing professionals, directly aligning
with the subject matter typically covered in advanced pharmacology coursework. This compilation is
suitable for comprehensive exam preparation, course review, and reinforcing understanding of clinical
pharmacology principles.
CONTENTS
01 Respiratory Conditions Q1–Q7
02 Diabetes Mellitus Management Q8–Q15
03 Infectious Disease & Antimicrobials Q16–Q35
Page 1
, 04 Allergic Rhinitis & Asthma Q36–Q39
05 Pharmacology Principles & Safety Q40–Q43
06 Endocrine & Metabolic Disorders Q44–Q48
07 Special Populations & Therapeutics Q49–Q55
E XA M Q U EST I O N S
Q1 QUESTION 1 OF 55
Mild persistent asthma. In addition to a Beta 2, you would add:
CORRECT ANSWER
An inhaled low dose corticosteroid
RATIONALE
The addition of an inhaled low-dose corticosteroid is indicated for mild persistent asthma to address underlying airway
inflammation, which is the primary driver of symptoms and exacerbations, rather than solely bronchodilation. This
addresses the GINA guideline recommendation for step-up therapy when symptoms are not controlled with reliever
inhalers alone.
Q2 QUESTION 2 OF 55
Pt presented with productive cough that has been troubling her because she "can't cough it all up". Which of the
following would be the most appropriate medicine to treat her with?
CORRECT ANSWER
Guaifenesin/Dextromethorphan (Robitussin DM)
RATIONALE
Guaifenesin is an expectorant that thins mucus, facilitating its removal, while dextromethorphan is a cough suppressant
that reduces the urge to cough, addressing the patient's difficulty in expectorating. The key concept tested is the
pharmacotherapy for managing productive coughs by addressing both mucus viscosity and the cough reflex.
Q3 QUESTION 3 OF 55
Page 2
, Pt presents to your clinic with daily asthma symptoms (mod. Persistent) Which medication would you prescribe in
addition to her SABA?
CORRECT ANSWER
Inhaled medium dose corticosteroid
RATIONALE
Daily symptoms of moderate persistent asthma indicate a need for a daily controller medication to reduce airway
inflammation, making an inhaled medium-dose corticosteroid the appropriate choice for long-term management. This
addresses the underlying inflammatory process, which is the key concept in controlling persistent asthma.
Q4 QUESTION 4 OF 55
60-year-old male with mild COPD. What type of med should he be on?
CORRECT ANSWER
Inhaled short acting bronchodilator as needed
RATIONALE
Symptomatic relief of bronchoconstriction in mild COPD is achieved with inhaled short-acting beta-agonists or
anticholinergics, administered on an as-needed basis for dyspnea. This addresses the underlying reversible airflow
obstruction and improves exercise tolerance.
Q5 QUESTION 5 OF 55
Which of the following types of medicine is used in the treatment of COPD?
CORRECT ANSWER
All of the above
RATIONALE
COPD management involves a multimodal approach including bronchodilators to open airways, corticosteroids to reduce
inflammation, and antibiotics for exacerbations, collectively addressing the disease's multifaceted pathophysiology. This
comprehensive strategy targets the reversible and irreversible components of airflow limitation and inflammation.
Q6 QUESTION 6 OF 55
Page 3
P R O F E S S I O N A L P R A C T I C E M AT E R I A L S
Regis University NU 641
Advanced Clinical
Pharmacology Exam 2
Questions & Answers 2026-
2027 (Rationales)
Verified Answers Exam Ready With Rationales
55 QUESTIONS
DOCUMENT OVERVIEW
This document presents 55 advanced clinical pharmacology exam questions, complete with correct
answers and detailed rationales. It is a valuable study resource for nursing professionals, directly aligning
with the subject matter typically covered in advanced pharmacology coursework. This compilation is
suitable for comprehensive exam preparation, course review, and reinforcing understanding of clinical
pharmacology principles.
CONTENTS
01 Respiratory Conditions Q1–Q7
02 Diabetes Mellitus Management Q8–Q15
03 Infectious Disease & Antimicrobials Q16–Q35
Page 1
, 04 Allergic Rhinitis & Asthma Q36–Q39
05 Pharmacology Principles & Safety Q40–Q43
06 Endocrine & Metabolic Disorders Q44–Q48
07 Special Populations & Therapeutics Q49–Q55
E XA M Q U EST I O N S
Q1 QUESTION 1 OF 55
Mild persistent asthma. In addition to a Beta 2, you would add:
CORRECT ANSWER
An inhaled low dose corticosteroid
RATIONALE
The addition of an inhaled low-dose corticosteroid is indicated for mild persistent asthma to address underlying airway
inflammation, which is the primary driver of symptoms and exacerbations, rather than solely bronchodilation. This
addresses the GINA guideline recommendation for step-up therapy when symptoms are not controlled with reliever
inhalers alone.
Q2 QUESTION 2 OF 55
Pt presented with productive cough that has been troubling her because she "can't cough it all up". Which of the
following would be the most appropriate medicine to treat her with?
CORRECT ANSWER
Guaifenesin/Dextromethorphan (Robitussin DM)
RATIONALE
Guaifenesin is an expectorant that thins mucus, facilitating its removal, while dextromethorphan is a cough suppressant
that reduces the urge to cough, addressing the patient's difficulty in expectorating. The key concept tested is the
pharmacotherapy for managing productive coughs by addressing both mucus viscosity and the cough reflex.
Q3 QUESTION 3 OF 55
Page 2
, Pt presents to your clinic with daily asthma symptoms (mod. Persistent) Which medication would you prescribe in
addition to her SABA?
CORRECT ANSWER
Inhaled medium dose corticosteroid
RATIONALE
Daily symptoms of moderate persistent asthma indicate a need for a daily controller medication to reduce airway
inflammation, making an inhaled medium-dose corticosteroid the appropriate choice for long-term management. This
addresses the underlying inflammatory process, which is the key concept in controlling persistent asthma.
Q4 QUESTION 4 OF 55
60-year-old male with mild COPD. What type of med should he be on?
CORRECT ANSWER
Inhaled short acting bronchodilator as needed
RATIONALE
Symptomatic relief of bronchoconstriction in mild COPD is achieved with inhaled short-acting beta-agonists or
anticholinergics, administered on an as-needed basis for dyspnea. This addresses the underlying reversible airflow
obstruction and improves exercise tolerance.
Q5 QUESTION 5 OF 55
Which of the following types of medicine is used in the treatment of COPD?
CORRECT ANSWER
All of the above
RATIONALE
COPD management involves a multimodal approach including bronchodilators to open airways, corticosteroids to reduce
inflammation, and antibiotics for exacerbations, collectively addressing the disease's multifaceted pathophysiology. This
comprehensive strategy targets the reversible and irreversible components of airflow limitation and inflammation.
Q6 QUESTION 6 OF 55
Page 3
